Actively Recruiting
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Led by Chang Gung Memorial Hospital · Updated on 2026-02-09
150
Participants Needed
1
Research Sites
305 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate. Immunotherapy has been established as the first-line standard of care for recurrent and metastatic head and neck cancer. However, patient selection is currently guided by the histological Combined Positive Score (CPS) (KN-048) or Tumor Proportion Score (TPS) (KN-040). A significant limitation is the inability to re-test tumor tissue when disease status changes necessitate therapeutic adjustment, as new tissue is often unavailable. Consequently, liquid biopsy, which allows for repeatable testing and thus constitutes a dynamic biomarker, becomes crucial. Nevertheless, its definitive role in predicting the efficacy of IT has yet to be thoroughly investigated. In this study, our team endeavors to define the CPS score of peripheral circulating tumor cells (CTCs) and evaluate the predictive ability of CTC TPS/CPS for clinical response, using objective clinical outcomes as the ultimate measure.
CONDITIONS
Official Title
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cancer patients aged 18 years or older with confirmed head and neck cancer planning immunotherapy
- Life expectancy of at least 3 months as assessed by a physician
- Available tissue biopsy or PD-L1 TPS/CPS staining results from this hospital
- Healthy subjects aged 18 years or older with no prior cancer diagnosis
You will not qualify if you...
- Presence of psychiatric disorders
- Uncontrolled medical complications
- Difficulty with blood collection or unwillingness to comply with follow-up blood draws
- Physician assessment deeming the individual unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Linkou Chang Gung Memorial Hospital
Taoyuan, City, Taiwan, 333
Actively Recruiting
Research Team
H
Hung-Ming Wang
CONTACT
C
Chia-Hsun Hsieh
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here